Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01936896 · ClinicalTrials.gov registry record · Phase 1
Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01936896 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 10 participants.
The verdict
NCT01936896, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Acute myocardial infarction is characterized by an intense inflammatory response. The degree of the response influences clinical outcome, with 'more' inflammation promoting heart failure. In this study we plan to determine whether treatment with plasma derived alpha-1 antitrypsin will quench the inflammatory response in patients with acute ST-segment elevation myocardial infarction (STEMI).
Interventions
- DRUG Alpha 1-Antitrypsin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-12 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01936896
The ClinicalTrials.gov registry entry for NCT01936896 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alpha 1-Antitrypsin is the first listed.
NCT01936896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01936896 about?
NCT01936896 is a clinical study titled "Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction". Acute myocardial infarction is characterized by an intense inflammatory response. The degree of the response influences clinical outcome, with 'more' inflammation promoting heart failure. In this study we plan to determine whether treatment with plasma derived alpha-1 antitrypsin will quench the in...
What is the current status of trial NCT01936896?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2013-12. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01936896?
The interventions under investigation include: Alpha 1-Antitrypsin (DRUG).
Who is sponsoring clinical trial NCT01936896?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.